Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL

16 Feb 2015

Abstract excerpt

PURPOSE: Histone deacetylase inhibitors (HDACi) have recently emerged as efficacious therapies that target epigenetic mechanisms in hematologic malignancies. One such hematologic malignancy, B-cell acute lymphoblastic leukemia (B-ALL), may be highly dependent on epigenetic regulation for leukemia development and maintenance, and thus sensitive to small-molecule inhibitors that target epigenetic mechanisms....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Lymphoblastic Leukemia research
Share to Acute Myeloid Leukemia Research
Share to Histone Deacetylase Inhibitors Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 25688158
DOI: 10.1158/1078-0432.ccr-14-1290

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALLPMID 25688158Read ↗

Preclinical activity of LBH589 alone or in combination with chemotherapy in a xenogeneic mouse model of human acute lymphoblastic leukemia.Semantic proximity Read ↗

Targeting class I histone deacetylases in cancer therapySemantic proximity Read ↗

Histone deacetylase inhibitors: targeting epigenetic regulation in the treatment of acute leukemiaSemantic proximity Read ↗

Histone Deacetylase Inhibitors in the Treatment of Hematological Malignancies and Solid TumorsSemantic proximity Read ↗

Nonredundant, isoform-specific roles of HDAC1 in glioma stem cells.Semantic proximity Read ↗

research paper: Differential expression of <i>HDAC3, HDAC7</i> and <i>HDAC9</i> is associated with prognosis and survival in childhood acute lymphoblastic leukaemiaSemantic proximity Read ↗

HDAC3 inhibition as a therapeutic strategy in T-cell acute lymphoblastic leukemia via the TYK2-STAT1-BCL2 signaling pathwaySemantic proximity Read ↗

Discovery of Novel Class of Histone Deacetylase Inhibitors as Anticancer AgentsSemantic proximity Read ↗

Mechanisms of HDACs in cancer developmentSemantic proximity Read ↗

Inhibition of histone deacetylases in cancer therapy: lessons from leukaemiaSemantic proximity Read ↗

HDAC Inhibitors in Acute Myeloid LeukemiaSemantic proximity Read ↗

Histone-Deacetylase Inhibitors for the Treatment of CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.